Recent

% | $
Quotes you view appear here for quick access.

Acusphere, Inc. Message Board

oncolyticpiedpiper 2 posts  |  Last Activity: Apr 20, 2016 9:17 AM Member since: Nov 6, 2007
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • oncolyticpiedpiper by oncolyticpiedpiper Apr 20, 2016 9:17 AM Flag

    Positive Clinical Data from CAVATAK™ and YERVOY® Combination
    presented at the 2016 AACR Annual Meeting
    Promising Response Rates and Good Tolerability in Late‐Stage Melanoma Patients
    19 April 2016, Sydney, Australia:  

    Viralytics Limited (ASX: VLA, OTC: VRACY) today presented
    positive initial data from its ongoing clinical trial evaluating the safety and anti‐cancer activity of
    its investigational drug candidate CAVATAK™ in combination with the checkpoint inhibitor
    YERVOY®1 (ipilimumab) in late‐stage melanoma patients.  The results were reported in a poster
    presentation at the American Association of Cancer Research (AACR) Annual Meeting 2016 in
    New Orleans, LA.
    The Phase 1b clinical trial, known as the MITCI (Melanoma Intra‐Tumoral CAVATAK and
    Ipilimumab) study, is being conducted at four US sites and has enrolled 11 advanced melanoma
    patients to date.  According to data from the first six patients evaluable for tumour assessment,
    objective responses have been confirmed by the independent Data Monitoring Committee in
    four patients, with one additional patient showing stable disease at Day 106.
    These results include two complete responses and two partial responses in patients with
    advanced melanoma, meaning their disease has spread to nearby lymph nodes (Stage III) or to
    other sites in the body (Stage IV).  The patient with stable disease has Stage IV melanoma with
    multiple liver metastases and had previously failed multiple earlier therapies, including the
    checkpoint inhibitors YERVOY and KEYTRUDA2 (pembrolizumab.)
    “The preliminary finding that, out of five patients not previously treated with YERVOY, four had
    clinically meaningful tumor regressions in sites injected with CAVATAK as well as visceral, lymph
    node and subcutaneous sites that were not injected is notable in light of published objective
    response rates for monotherapy (CAVATAK: 28.1% and YERVOY: 11%3
    ) in patients with advanced
    melanoma.” said Lead Investigator Dr Brendan Curti, MD.

  • Reply to

    Today's News Just Made Us a $10.00+ Stock

    by rootbound43 Feb 18, 2016 10:37 AM
    oncolyticpiedpiper oncolyticpiedpiper Feb 18, 2016 10:48 AM Flag

    Have they announced a date for results? TIA

ACUS
0.042+0.002(+4.74%)Apr 29 1:18 PMEDT